Metabolic Syndrome and Female Breast Cancer

Metabolic Syndrome and Female Breast Cancer: a Case-control Study in Southern Brazil

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02282592

Enrollment

164

Registered

2014-11-04

Start date

2013-11-30

Completion date

2014-10-31

Last updated

2014-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Metabolic syndrome, case-control study, Breast cancer

Brief summary

The role among metabolic syndrome and breast cancer risk is not well understood and must be further explored. The objective of this study is to evaluate the association between metabolic syndrome and breast cancer in Southern Brazil. In this case-control study, breast cancer patients and controls without malignant disease, matched for age (±5 years) and menopausal status, were interviewed and asked to make a glucose, HDL-cholesterol and triglycerides test. Waist circumference and blood pressure were measured using standardized procedures. Metabolic Syndrome was considered by NCEP ATP III (2001) and IDF (2006) definitions. Cases and controls were compared in relation to the presence of diagnosed MetS (yes/no), number of metabolic abnormalities identified (1 to 5) for each definition, and according to each metabolic abnormality cutoff point.

Interventions

OTHERObservation about the presence of metabolic syndrome

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Yes

Inclusion criteria

* For cases: having newly diagnosed breast cancer without adjuvant or neoadjuvant treatment; * For controls: having no evidence of cancer; be matched for age and menopausal status with controls

Exclusion criteria

* Women with a recidivated tumor, HIV infection, renal, heart or liver disease, hypothyroidism or hyperthyroidism, mobility or neurological limitations, chronicle use of corticosteroids, pacemakers or identified with severe edema were excluded.

Design outcomes

Primary

Measure	Time frame
Odds Ratio for Breast Cancer according to the presence of Metabolic Syndrome and its components	Participants will be evaluated only once before the first appointment with the oncologist (cases with a biopsy) and gynecologist (controls). The blood test results for Metabolic Syndrome parameters were collected in an expected average of 30 days.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026